Protocol Title: A Phase II Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with AGEN2034 in Subjects with Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

Target Population: Locally Advanced or Metastatic Cervical Cancer

Summary: This is a Phase II study of AGEN1884 in combination with AGEN2034 in subjects with advanced solid tumors including cervical cancer. AGEN2034 is a novel, fully human monoclonal immunoglobulin G4 (IgG4) antibody, designed to block program cell death-1 (PD-1). AGEN1884 is a novel, fully human monoclonal immunoglobulin G1 (IgG1) antibody, designed to block cytotoxic T lymphocyte antigen-4 (CTLA-4).

Key Inclusion Criteria:
- Confirmed diagnosis of metastatic or locally advanced, unresectable squamous-cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix; and have relapsed after a platinum-containing doublet administered for treatment of advanced (recurrent, unresectable, or metastatic) disease.
- Must have measurable disease.
- Life expectancy of at least 3 months and an ECOG performance status of 0 or 1.
- Adequate organ function
- No history of prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous-cell carcinoma of the skin, in situ cervical cancer, or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
  - Note: In Phase 2, the history and time requirement for no evidence of disease for 5 years does not apply to the cancer for which the subject is enrolled in the study.
- In Phase 2, subjects must have provided sufficient and adequate formalin fixed tumor tissue sample preferably from a biopsy of a tumor lesion either at the time of or after the diagnosis of advanced or metastatic disease has been made AND from a site not previously irradiated.

Key Exclusion Criteria:
- Received prior systemic cytotoxic chemotherapy, biological therapy, radiation therapy, OR major surgery within 3 weeks or 5 half-lives (whichever is longer) of the first dose of trial treatment.
- Received prior therapy with any antibody/drug targeting T-cell co-regulatory proteins (immune checkpoints) such as anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibodies.
- Persisting toxicity related to prior therapy NCI-CTCAE version 4.03 Grade >1 severity.
- Is expected to require any other form of systemic or localized antineoplastic therapy while on trial.
- Has known severe hypersensitivity reactions to monoclonal antibodies (NCI-CTCAE Grade ≥3), any history of anaphylaxis, or uncontrolled asthma (i.e., ≥3 features of partly controlled asthma).
- Has a CNS tumor, metastasis(es), and/or carcinomatous meningitis identified either on the baseline brain imaging obtained during the screening period OR identified prior to consent.
- Has had an allogeneic tissue/solid organ transplant.
- Has an active infection requiring intravenous systemic therapy.
- Has known history of Human Immunodeficiency Virus (HIV) or active Hepatitis B, Hepatitis C or tuberculosis.
- Has clinically significant (i.e., active) cardiovascular disease.

Contacts:
- Principal Investigator: Katrina Wade, MD
- Research Nurses (RN): Amanda Struckhoff (amanda.struckhoff@ochsner.org, ext. 23682)
  Amanda Woolery (amanda.woolery@ochsner.org, ext. 20275)

For additional information: https://clinicaltrials.gov/ct2/show/NCT03495882